| 000 | 01872 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250515061310.0 | ||
| 264 | 0 | _c20070514 | |
| 008 | 200705s 0 0 eng d | ||
| 022 | _a0022-2623 | ||
| 024 | 7 |
_a10.1021/jm061247v _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTao, Zhi-Fu | |
| 245 | 0 | 0 |
_aStructure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. _h[electronic resource] |
| 260 |
_bJournal of medicinal chemistry _cApr 2007 |
||
| 300 |
_a1514-27 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xchemical synthesis |
| 650 | 0 | 4 |
_aCamptothecin _xpharmacology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aCheckpoint Kinase 1 |
| 650 | 0 | 4 | _aCrystallography, X-Ray |
| 650 | 0 | 4 | _aDNA Damage |
| 650 | 0 | 4 |
_aDoxorubicin _xpharmacology |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aDrug Screening Assays, Antitumor |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMacrocyclic Compounds _xchemical synthesis |
| 650 | 0 | 4 | _aModels, Molecular |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xchemical synthesis |
| 650 | 0 | 4 |
_aProtein Kinases _xchemistry |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_aUrea _xanalogs & derivatives |
| 700 | 1 | _aWang, Le | |
| 700 | 1 | _aStewart, Kent D | |
| 700 | 1 | _aChen, Zehan | |
| 700 | 1 | _aGu, Wendy | |
| 700 | 1 | _aBui, Mai-Ha | |
| 700 | 1 | _aMerta, Philip | |
| 700 | 1 | _aZhang, Haiying | |
| 700 | 1 | _aKovar, Peter | |
| 700 | 1 | _aJohnson, Eric | |
| 700 | 1 | _aPark, Chang | |
| 700 | 1 | _aJudge, Russell | |
| 700 | 1 | _aRosenberg, Saul | |
| 700 | 1 | _aSowin, Thomas | |
| 700 | 1 | _aLin, Nan-Horng | |
| 773 | 0 |
_tJournal of medicinal chemistry _gvol. 50 _gno. 7 _gp. 1514-27 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1021/jm061247v _zAvailable from publisher's website |
| 999 |
_c16908608 _d16908608 |
||